Audentes Therapeutics (NASDAQ:BOLD) Stock Rating Reaffirmed by Chardan Capital

Audentes Therapeutics (NASDAQ:BOLD)‘s stock had its “neutral” rating reissued by analysts at Chardan Capital in a research report issued on Wednesday, Marketbeat reports. They presently have a $60.00 target price on the biotechnology company’s stock. Chardan Capital’s price target suggests a potential upside of 1.33% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. BidaskClub lowered Audentes Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, November 8th. William Blair reaffirmed a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, August 7th. BMO Capital Markets cut Audentes Therapeutics from an “outperform” rating to a “market perform” rating and lifted their price objective for the stock from $47.00 to $60.00 in a report on Tuesday. Wedbush downgraded Audentes Therapeutics from an “outperform” rating to a “neutral” rating and set a $60.00 target price on the stock. in a research report on Tuesday. Finally, Raymond James downgraded Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, sixteen have given a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $46.29.

Shares of NASDAQ BOLD opened at $59.21 on Wednesday. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of -17.41 and a beta of 1.77. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $59.48. The firm has a 50-day moving average price of $29.57 and a 200 day moving average price of $33.41.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.07. During the same quarter last year, the business earned ($0.97) EPS. Research analysts forecast that Audentes Therapeutics will post -4.13 earnings per share for the current fiscal year.

In other Audentes Therapeutics news, Director Louis G. Lange sold 10,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the completion of the transaction, the director now owns 276,044 shares of the company’s stock, valued at $8,877,575.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew R. Patterson sold 14,426 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $30.00, for a total value of $432,780.00. Following the completion of the transaction, the chief executive officer now directly owns 127,820 shares of the company’s stock, valued at $3,834,600. The disclosure for this sale can be found here. Insiders own 5.30% of the company’s stock.

Several large investors have recently modified their holdings of the company. Great Point Partners LLC boosted its stake in shares of Audentes Therapeutics by 29.2% during the third quarter. Great Point Partners LLC now owns 2,485,000 shares of the biotechnology company’s stock valued at $69,804,000 after acquiring an additional 562,063 shares during the last quarter. BlackRock Inc. increased its position in Audentes Therapeutics by 14.2% during the 2nd quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock worth $126,204,000 after purchasing an additional 413,768 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in Audentes Therapeutics by 118.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 592,947 shares of the biotechnology company’s stock valued at $22,449,000 after purchasing an additional 321,756 shares during the last quarter. Millennium Management LLC raised its stake in Audentes Therapeutics by 49.2% in the 3rd quarter. Millennium Management LLC now owns 773,279 shares of the biotechnology company’s stock valued at $21,721,000 after purchasing an additional 255,086 shares during the last quarter. Finally, Nuveen Asset Management LLC purchased a new position in Audentes Therapeutics in the 2nd quarter valued at about $8,653,000. Institutional investors and hedge funds own 98.08% of the company’s stock.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Further Reading: What is the Gross Domestic Product (GDP)?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.